BI 224436: Difference between revisions

BI 224436
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Pharmacokinetic data
Elimination half-life	7 hrs (simulated)
Identifiers
	IUPAC name (2S)-[4-(2,3-Dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methyl-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid;
CAS Number	1155419-89-8;
PubChem CID	66561902;
ChemSpider	32698770;
UNII	99A996378Y;
CompTox Dashboard (EPA)	DTXSID601029847 ;
Chemical and physical data
Formula	C27H26N2O4
Molar mass	442.515 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4;
	InChI InChI=1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1; Key:MIXIIJCBELCMCZ-VWLOTQADSA-N;

Content deleted Content added

Inline

Revision as of 21:11, 30 August 2017

BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.^[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.^[3]^[4]

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

@@ Line 13: / Line 13: @@
 | ATC_suffix =
 <!--Chemical data-->
-| C=24 | H=25 | N=1 | O=4
+| C=27 | H=26 | N=2 | O=4
 | molecular_weight = 442.515 g/mol
 | smiles = CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4